Tumor Immunology and Immunotherapy Program

14.0翻译后摘要：肿瘤免疫学和免疫治疗（TII）计划 TII计划是一个跨学科的计划，追求高度创新的基础科学研究， 转化/临床试验。TII计划的总体目标是开发和实施基于免疫的 监测和治疗癌症的策略。为了实现这一目标，该计划侧重于三个研究目标：目标1： 基于细胞和调控途径的靶向癌症免疫疗法-开发基于细胞和调控途径的 能够减少或监测恶性细胞生长的通路靶向癌症免疫疗法。 目标2：校准免疫调节-制定克服肿瘤诱导的免疫抑制的策略 并减轻免疫治疗相关的副作用。目标3：癌症和炎症-阐明作用 感染和炎症反应在癌症发展中的作用。TII计划是一项跨学科的研究 和教育计划。项目成员致力于了解恶性肿瘤的免疫调节 并将这些知识转化为新的诊断和治疗方案的发展。的 TII计划有35个成员，包括18个正式成员和17个准成员，他们进行癌症- 重点研究得到1660万美元年度直接成本资金的支持（总计2170万美元），其中包括190万美元 (11.2%）来自NCI，1050万美元来自其他同行评审来源。TII计划成员获得430万美元 每年从非同行审查的资金来源。在此期间，TII成员撰写了371篇 癌症相关出版物，其中15%来自方案内，30%来自方案间， 6%来自方案内和方案间合作; 64%的出版物包括与外部合作 调查人员，反映了TII计划的高国家影响力，14%的TII出版物在期刊上发表 影响因子≥10。TII教师的研究工作得到了广泛使用所有共享 服务TII计划与马里兰州马琳大学的其他研究计划相结合 斯图尔特·格林鲍姆综合癌症中心（UMGCCC）和TII与社区互动 外展和参与（COE）作为一个桥梁，以确定社区在我们的集水区的需求。

14.0 Abstract: Tumor Immunology and Immunotherapy (TII) Program The TII Program is an interdisciplinary program that pursues highly innovative basic science research and translational/clinical trials. The overall goal of the TII Program is to develop and implement immune-based strategies to monitor and treat cancer. To achieve this goal, the program focuses on three research aims: Aim 1: Cell-based and regulatory pathway-targeted cancer immunotherapies—Develop cell-based and regulatory pathway-targeted cancer immunotherapies that are capable of reducing or monitoring malignant cell growth. Aim 2: Calibrating immune regulation—Develop strategies to overcome tumor-induced immunosuppression and to mitigate immunotherapy-related adverse effects. Aim 3: Cancer and inflammation—Elucidate the roles of infection and inflammatory responses in cancer development. The TII Program is an interdisciplinary research and educational program. Program members are dedicated to understanding the immune regulation of malignant disease and translating this knowledge into the development of novel diagnostic and treatment regimens. The TII Program has 35 members, including 18 full members and 17 associate members, who conduct cancer- focused research supported by $16.6 million annual direct cost funding ($21.7 million total), including $1.9 million (11.2%) from NCI and $10.5 million from other peer-reviewed sources. TII Program members receive $4.3 million annually from non–peer-reviewed funding sources. During this funding period, TII members authored 371 cancer-related publications, of which 15% resulted from intraprogrammatic, 30% from interprogrammatic, and 6% from intra and interprogrammatic collaborations; 64% of publications include collaborations with external investigators, reflecting the high national impact of the TII Program, and 14% of TII publications were in journals with an impact factor ≥10. The research efforts of TII faculty are supported by extensive use of all shared services. The TII Program is integrated with the other research programs at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) and TII interacts with Community Outreach and Engagement (COE) as a bridge to identify the needs of communities in our catchment area.